Breast diseases

PubMed Free Full Text

Breast cancer treatment

Africa

• JCO Global Oncology
  • Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review [2023]

Arab countries

• Health and Quality of Life Outcomes
  • Quality of life in Arab women with breast cancer: a review of the literature [2016]

Asia

• BMJ Open
  • Health-related quality of life in Asian patients with breast cancer: a systematic review [2018]

• Journal of Breast Cancer
  • Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide [2016]

• PLoS ONE
  • Predicting Survival of De Novo Metastatic Breast Cancer in Asian Women: Systematic Review and Validation Study [2014]

• Systematic Reviews
  • Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis [2024]

Australia

• Australian Journal of General Practice
  • Update on the management of early-stage breast cancer [2019]
  • Advanced breast cancer [2019]

• PLoS ONE
  • Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice [2014]

Austria

• Wiener klinische Wochenschrift
  • Updated Austrian treatment algorithm in HER2+ metastatic breast cancer [2022]
  • Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update [2022]

Brazil

• Epidemiologia e Serviços de Saúde
  • Frequency and factors associated with delay in breast cancer treatment in Brazil, according to data from the Oncology Panel, 2019-2020 [2023]

• International Journal of Environmental Research and Public Health
  • Waiting Time between Breast Cancer Diagnosis and Treatment in Brazilian Women: An Analysis of Cases from 1998 to 2012 [2020]

• Lancet Global Health
  • Racial disparities in breast cancer survival after treatment initiation in Brazil: a nationwide cohort study [2024]

Bulgaria

• Frontiers in Public Health
  • Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria [2023]

Canada

• Breast Cancer Research and Treatment
  • A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles [2022]

• Canadian Agency for Drugs and Technologies in Health
  • Regional Chemotherapy for the Treatment of Breast Cancer: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines [2018]

• Canadian Family Physician
  • Breast Cancer Survivorship Tool [2020]
  • Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians [2016]

• Canadian Journal of Physiology and Pharmacology
  • Preventing broken hearts in women with breast cancer: a concise review on chemotherapy-mediated cardiotoxicity [2024]

• Current Oncology
  • Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting [2024]
  • Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion [2023]
  • Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape [2023]
  • Systemic treatment approaches in her2-negative advanced breast cancer—guidance on the guidelines [2015]
  • Optimal systemic therapy for early breast cancer in women: a clinical practice guideline [2015]
  • Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor–positive metastatic breast cancer in Canada [2013]

• Ontario Health
  • Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Cancer Care Ontario’s Position Statement on Guidelines for Breast Cancer Well Follow-Up Care [2012]

Canada, United States

• CA: A Cancer Journal for Clinicians
  • Clinical practice guidelines on the evidence-based use of integrative therapies during and following breast cancer treatment [2017]

Central and Eastern Europe

• Pathology & Oncology Research
  • Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer [2022]
  • Breast Cancer Survivorship Programme: Follow-Up, Rehabilitation, Psychosocial Oncology Care. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer [2022]

China

• Annals of Translational Medicine
  • Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study [2021]

• Cancer Biology & Medicine
  • Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification [2022]

• Chinese Medical Journal
  • Clinical practice guidelines for neoadjuvant therapy in patients with early-stage breast cancer: Chinese Society of Breast Surgery practice guidelines 2022 [2024]
  • Clinical practice guidelines for breast cancer implantable intravenous infusion ports: Chinese Society of Breast Surgery practice guidelines 2021 [2021]

• Clinical Breast Cancer
  • Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China [2024]

• Frontiers in Oncology
  • Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China [2021]

• Frontiers in Public Health
  • The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012) [2023]

• Journal of Oncology
  • Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China [2021]

• Supportive Care in Cancer
  • Financial toxicity in female patients with breast cancer: a national cross-sectional study in China [2022]

China, United States

• JAMA Network Open
  • Trends in Disparities and Transitions of Treatment in Patients With Early Breast Cancer in China and the US, 2011 to 2021 [2023]

• Scientific Reports
  • Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US [2024]

Denmark

• Acta Oncologica
  • Survival outcomes for HER2-low breast cancer: Danish national data [2024]

• Journal of the National Cancer Institute
  • The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis [2022]

Egypt

• Journal of the Egyptian National Cancer Institute
  • Primary therapy of early breast cancer: Egyptian view of 2021 St. Gallen consensus [2022]

Europe

• BMC Cancer
  • Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe [2015]

• BMC Health Services Research
  • Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries [2020]

• Clinical Breast Cancer
  • A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer [2017]

• Critical Reviews in Oncology/Hematology
  • Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies [2022]

• European Society for Medical Oncology
  • Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies [2020]

• European Society of Breast Cancer Specialists
  • EUSOMA quality indicators for non-metastatic breast cancer: An update [2024]
  • European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care [2023]

• Journal of Cancer Research and Clinical Oncology
  • Therapy delay due to COVID-19 pandemic among European women with breast cancer: prevalence and associated factors [2023]

Europe, United States

• Cancer Treatment Reviews
  • Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality [2022]

• Cancers
  • FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis [2020]

France

• BMC Medicine
  • Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women [2023]

• Breast Cancer Research and Treatment
  • Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database [2024]

• ESMO Open
  • Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort [2024]

• JAMA Network Open
  • Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France [2022]

Germany

• BMC Cancer
  • The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients [2015]

• Breast Cancer
  • Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study [2018]

• Breast Care
  • International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts [2020]
  • Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019) [2019]
  • ABC4 Consensus: Assessment by a German Group of Experts [2018]
  • ABC3 Consensus: Assessment by a German Group of Experts [2016]
  • 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus – Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts [2015]
  • Guideline Conformity Treatment in Young Women with Early-Onset Breast Cancer in Germany [2014]
  • 13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus – Opinion of a German Team of Experts (Zurich 2013) [2013]

• Deutsche Gesellschaft für Radioonkologie
  • Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously? [2021]

• Geburtshilfe und Frauenheilkunde
  • Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference [2021]
  • AGO Algorithms for the Treatment of Breast Cancer: Update 2021 [2021]
  • ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results [2020]
  • Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer [2018]
  • 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts [2018]
  • Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus [2017]
  • ABC3 Consensus Commented from the Perspective of the German Guidelines [2016]
  • Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015) [2015]

• Institute for Quality and Efficiency in Health Care
  • Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V [2017]

• International Journal of Cancer
  • Time trends of neoadjuvant chemotherapy for early breast cancer [2020]

• Journal of Cancer Research and Clinical Oncology
  • Contributing and limiting factors to guideline-adherent therapy in senior and elderly breast cancer patients: a questionnaire-based cross-sectional study using clinical and cancer registry data in Germany [2023]

Ghana

• PLoS ONE
  • Geospatial availability of breast cancer treatment modalities and hypothetical access improvement in Ghana: A nationwide survey [2023]

Greece

• BMC Health Services Research
  • Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study [2015]

Hong Kong

• Hong Kong Medical Journal
  • Preoperative considerations and benefits of neoadjuvant chemotherapy: insights from a 12-year review of the Hong Kong Breast Cancer Registry [2023]

India

• Indian Journal of Medical Research
  • Consensus on contentious issues relevant for breast cancer management for the Indian scenario: Statements following a multicentre expert group meeting [2021]
  • Breast cancer survivorship in India [2021]

• Indian Journal of Surgery
  • Indian Solutions for Indian Problems—Association of Breast Surgeons of India (ABSI) Practical Consensus Statement, Recommendations, and Guidelines for the Treatment of Breast Cancer in India [2017]

• South Asian Journal of Cancer
  • Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India [2021]

International

• Annals of Oncology
  • Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023 [2023]
  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [2021]
  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [2015]

• BMJ Open
  • Evidence-based recommendations on care for breast cancer survivors for primary care providers: a review of evidence-based breast cancer guidelines [2017]

• Breast
  • Global representativeness and impact of funding sources in cost-effectiveness research on systemic therapies for advanced breast cancer: A systematic review [2024]
  • 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) [2024]
  • The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review [2022]
  • Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review [2022]
  • Customizing early breast cancer therapies - The 2021 St. Gallen International Breast Cancer Consensus Conference [2022]
  • Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review [2020]

• Breast Care
  • St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer [2021]
  • St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment [2019]

• Breast Health Global Initiative
  • Breast cancer treatment: A phased approach to implementation [2020]

• Cancer Genomics & Proteomics
  • Pharmacogenetics of Toxicities Related to Endocrine Treatment in Breast Cancer: A Systematic Review and Meta-analysis [2024]

• Cancer Treatment Reviews
  • Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge [2021]

• Cochrane Database of Systematic Reviews
  • Psychological interventions for women with non-metastatic breast cancer [2023]
  • Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer [2020]

• European Society for Medical Oncology
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [2020]
  • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [2018]
  • 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) [2017]

• Geburtshilfe und Frauenheilkunde
  • Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel [2021]

• Health Expectations
  • Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review [2020]

• JAMA Network Open
  • Financial Toxicity Among Patients With Breast Cancer Worldwide: A Systematic Review and Meta-analysis [2023]

• JCO Clinical Cancer Informatics
  • Mapping the Evidence on the Impact of mHealth Interventions on Patient-Reported Outcomes in Patients With Breast Cancer: A Systematic Review [2024]

• JCO Global Oncology
  • Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact [2021]

• Journal of Cancer Survivorship
  • Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines [2022]

• Journal of Comparative Effectiveness Research
  • A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib [2024]

• NPJ Breast Cancer
  • Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic [2020]

• Oncologist
  • Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel [2022]

• Oncotarget
  • Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer [2018]

• Patient
  • Differences in Preferences for Drug Therapy Between Patients with Metastatic Versus Early-Stage Breast Cancer: A Systematic Literature Review [2024]

• PLoS ONE
  • Global treatment costs of breast cancer by stage: A systematic review [2018]

Ireland, Netherlands

• PLoS ONE
  • Treatment Strategies and Survival of Older Breast Cancer Patients – An International Comparison between the Netherlands and Ireland [2015]

Italy

• BMC Cancer
  • An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project [2018]

• Breast
  • Influence of adherence with guideline-driven recommendations on survival in women operated for breast cancer: Real-life evidence from Italy [2020]

• Cancer Treatment Reviews
  • Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project [2024]

Japan

• Breast Cancer
  • The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment [2024]
  • The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition [2023]
  • The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition [2020]
  • Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer [2013]

Latin America

• JCO Global Oncology
  • Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines [2024]

Latin America and the Caribbean

• Oncologist
  • Health-Related Quality of Life in Patients with Breast Cancer in Latin America and the Caribbean: A Systematic Review and Meta-Analysis [2021]

Low and middle income countries

• BMC Cancer
  • Essential medicines for breast cancer in low and middle income countries [2015]

• Breast Health Global Initiative
  • Supportive care during treatment for breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement [2013]
  • Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement [2013]

Morocco

• Breast Journal
  • Management of breast cancer during COVID-19 pandemic in Morocco [2020]

Netherlands

• BMC Cancer
  • Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands [2016]

• Breast Cancer Research and Treatment
  • Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry [2024]
  • The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients [2021]
  • The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands [2021]

Netherlands, United Kingdom

• European Journal of Cancer
  • Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands - A comparison of two national prospective longitudinal multi-centre cohort studies [2022]

New Zealand

• Breast
  • New Zealand experience with implementation of the ESO-ESMO consensus guidelines for advanced breast cancer-report of achievements and lessons learned [2022]

• International Journal of Environmental Research and Public Health
  • Use of Non-Cancer Medications in New Zealand Women at the Diagnosis of Primary Invasive Breast Cancer: Prevalence, Associated Factors and Effects on Survival [2020]

Nigeria

• ecancermedicalscience
  • Assessment of guideline adherence in breast cancer management among oncologists in Nigeria [2021]

Norway

• Breast Cancer Research and Treatment
  • Stage-specific survival has improved for young breast cancer patients since 2000: but not equally [2020]

Republic of Korea

• Cancer Research and Treatment
  • Quality Assessment and Trend for Breast Cancer Treatment Practice across South Korea Based on Nationwide Analysis of Korean Health Insurance Data during 2013-2017 [2023]

• ClinicoEconomics and Outcomes Research
  • Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea [2016]

• Journal of Breast Cancer
  • Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013 [2015]
  • Meeting Highlights: The First Korean Breast Cancer Treatment Consensus Conference [2014]

• Journal of Korean Medical Science
  • Nationwide Analysis of Treatment Patterns for Korean Breast Cancer Survivors Using National Health Insurance Service Data [2018]

• Journal of the American Heart Association
  • Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea [2022]

• Nutrients
  • Adherence to Guidelines for Cancer Survivors and Health-Related Quality of Life among Korean Breast Cancer Survivors [2015]

Serbia

• JBUON
  • Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE [2018]

Singapore

• Scientific Reports
  • Impact of deviation from guideline recommended treatment on breast cancer survival in Asia [2020]

Spain

• Breast Cancer Research and Treatment
  • Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort [2022]

• Clinical and Translational Oncology
  • Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey [2024]
  • Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer [2022]
  • Defining the optimal sequence for the systemic treatment of metastatic breast cancer [2016]

• Health and Quality of Life Outcomes
  • Health-related quality of life in Spanish breast cancer patients: a systematic review [2011]

• Journal of Drug Assessment
  • Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists [2019]

• Oncologist
  • GEICAM Guidelines for the Management of Patients with Breast Cancer During Spain's COVID-19 Pandemic [2020]

• Scientific Reports
  • Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study [2021]

• Sociedad Española de Oncología Médica
  • SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022) [2023]
  • SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) [2023]
  • SEOM clinical guidelines in early stage breast cancer (2018) [2019]
  • SEOM clinical guidelines in advanced and recurrent breast cancer (2018) [2019]
  • Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC) [2018]
  • SEOM clinical guidelines in metastatic breast cancer 2015 [2015]

Sub-Saharan Africa

• Breast Cancer Research
  • Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study [2019]

• JAMA Network Open
  • Survival Patterns Among Patients With Breast Cancer in Sub-Saharan Africa: A Systematic Review and Meta-Analysis [2024]

• Lancet Oncology
  • Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study [2022]

Sweden

• Acta Oncologica
  • Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences [2024]

Switzerland

• Cancers
  • Management and Outcome of Young Women (<=40 Years) with Breast Cancer in Switzerland [2022]

Taiwan

• Breast
  • Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan [2021]

• Scientific Reports
  • Association of treatment delay and stage with mortality in breast cancer: a nationwide cohort study in Taiwan [2022]
  • Health Services Utilisation in Breast Cancer Survivors in Taiwan [2014]

Turkey

• Turkish Journal of Surgery
  • Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak [2020]

United Kingdom

• BMJ Open
  • Societal costs of chemotherapy in the UK: an incidence-based cost-of-illness model for early breast cancer [2021]

• Breast
  • Management and outcomes for older women with early breast cancer treated with primary endocrine therapy (PET) [2024]

• British Journal of Cancer
  • Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England [2023]
  • A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program [2023]
  • Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study [2021]

• Cancer Biology & Medicine
  • The decision-making process for senior cancer patients: treatment allocation of older women with operable breast cancer in the UK [2015]

• Indian Journal of Surgery
  • Breast Cancer Management Guidelines During COVID-19 Pandemic [2020]

• National Institute for Health and Care Excellence
  • Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations [2024]
  • Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy [2023]
  • Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies [2022]
  • Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2022]
  • Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer [2022]
  • Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence [2022]
  • Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2021]
  • Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [2021]
  • Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2019]
  • Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen [2018]
  • Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2017]
  • Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [2017]
  • Everolimus with exemestane for treating advanced breast cancer after endocrine therapy [2016]
  • Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens [2016]
  • Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 [2012]
  • Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer [2012]
  • Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer [2011]
  • Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer [2006]

United States

• American Cancer Society
  • American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline [2015]

• American College of Radiology
  • Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer
  • Locally Advanced Breast Cancer

• American Society of Breast Surgeons
  • Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer: Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries [2021]

• American Society of Clinical Oncology
  • Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline Q and A [2024]
  • Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline [2024]
  • Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update [2024]
  • Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update [2024]
  • Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update [2023]
  • Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update [2023]
  • Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A [2023]
  • Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update Q and A [2022]
  • Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update [2022]
  • Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update Q and A [2022]
  • Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update [2022]
  • Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update [2022]
  • Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A [2022]
  • Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update [2022]
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline [2021]
  • Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update [2021]
  • Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update [2021]
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update [2020]
  • Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline [2019]
  • Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update [2018]
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update [2018]
  • Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update [2018]
  • Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline [2018]
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update [2018]
  • Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update [2017]
  • Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline [2016]
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression [2016]
  • Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update [2013]
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
  • Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
  • Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer
  • Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative

• ASCO Educational Book
  • Advances in the Management of Menopausal Symptoms, Fertility Preservation, and Bone Health for Women With Breast Cancer on Endocrine Therapy [2023]
  • What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care [2020]

• Breast
  • Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes [2022]

• Breast Cancer : Basic and Clinical Research
  • Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database [2020]

• Breast Cancer : Targets and Therapy
  • Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis [2021]

• Breast Cancer Research and Treatment
  • Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer [2024]
  • Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis [2024]
  • Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium [2020]
  • Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG) [2018]
  • Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) [2018]
  • Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines [2013]

• Cancer Medicine
  • Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score =26: A National Cancer Database analysis [2024]
  • Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey [2015]

• Cancers
  • Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer [2022]

• Current Breast Cancer Reports
  • Lessons Learned: Management of Breast Cancer Patients throughout the COVID-19 Pandemic [2021]

• Expert Review of Anticancer Therapy
  • Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimens [2022]

• Food and Drug Administration
  • U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review [2022]
  • FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer [2015]

• JAMA Network Open
  • Racial Disparities in Receipt of Guideline-Concordant Care in Older Adults With Early Breast Cancer [2024]
  • Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations [2024]
  • Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer [2020]

• JAMA Oncology
  • Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States [2017]

• JCO Oncology Practice
  • Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach [2020]

• JNCCN
  • Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials [2022]

• Journal of Cancer
  • Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer [2014]

• Journal of Cancer Survivorship
  • Current practice patterns and gaps in guideline-concordant breast cancer survivorship care [2023]

• Journal of Clinical Oncology
  • Late Breast Cancer Survivorship: Side Effects and Care Recommendations [2022]

• Journal of Managed Care & Specialty Pharmacy
  • Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer [2024]

• National Cancer Institute
  • Childhood Breast Cancer Treatment (PDQ®)
  • Breast Cancer Treatment (PDQ®)

• National Comprehensive Cancer Network
  • Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology [2024]
  • NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 [2023]
  • NCCN resource-stratified and harmonized guidelines: A paradigm for optimizing global cancer care [2020]

• Society for Immunotherapy of Cancer
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer [2021]

• Society for Integrative Oncology
  • Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment [2017]

Western countries

• Maturitas
  • The effects of lifestyle and behavioural interventions on cancer recurrence, overall survival and quality of life in breast cancer survivors: A systematic review and network meta-analysis [2024]

{Related topics}

• Topic
  • Breast cancer treatment: vinca alkaloids
  • Breast cancer treatment: tyrosine kinase inhibitors
  • Breast cancer treatment: taxanes
  • Breast cancer treatment: surgery, radiotherapy
  • Breast cancer treatment: monoclonal antibodies
  • Breast cancer treatment: epothilones
  • Breast cancer treatment: bisphosphonates
  • Breast cancer treatment: aromatase inhibitors
  • Breast cancer treatment: antimetabolites
  • Breast cancer treatment: antiestrogens
  • Breast cancer treatment: anthracyclines
  • Breast cancer